News & Updates
Filter by Specialty:

Tapinarof safe, efficacious for moderate-to-severe AD in children, adults
Treatment with tapinarof cream 1% once daily demonstrates significant efficacy with a favourable safety profile among adults and children with moderate-to-severe atopic dermatitis (AD), a study has shown.
Tapinarof safe, efficacious for moderate-to-severe AD in children, adults
06 Sep 2024
Dupilumab prevents atopic march progression in children with AD
Use of dupilumab effectively lowers the risk of atopic march progression as opposed to conventional immunomodulatory therapies in paediatric patients with atopic dermatitis (AD), reports a recent study.
Dupilumab prevents atopic march progression in children with AD
06 Sep 2024
VTE incidence similar among common SGAs
The incidence of venous thromboembolism (VTE) does not appear to significantly differ among patients treated with second-generation antipsychotics (SGAs) such as risperidone, olanzapine, or aripiprazole, results of a study have shown.
VTE incidence similar among common SGAs
05 Sep 2024
Colchicine on par with NSAID for pericarditis prevention in HFrEF, CAD
The incidence of pericarditis recurrence or documentation of incessant symptoms within 12 months of the index hospitalization does not differ between heart failure (HF) patients treated with colchicine monotherapy and those who received NSAID monotherapy.
Colchicine on par with NSAID for pericarditis prevention in HFrEF, CAD
04 Sep 2024
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
In older patients with untreated mantle cell lymphoma (MCL), the addition of the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to bendamustine and rituximab (ABR) conferred a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a favourable trend for overall survival (OS), findings from the phase III ECHO trial have shown.